545 related articles for article (PubMed ID: 34922630)
21. Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia.
Ilhan O; Narli Ozdemir Z; Dalva K; Arslan A; Okay Ozgeyik M; Ipek S; Saydam G; Haznedaroglu IC
Int J Lab Hematol; 2021 Oct; 43(5):1110-1116. PubMed ID: 33834631
[TBL] [Abstract][Full Text] [Related]
22. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.
Bolton-Gillespie E; Schemionek M; Klein HU; Flis S; Hoser G; Lange T; Nieborowska-Skorska M; Maier J; Kerstiens L; Koptyra M; Müller MC; Modi H; Stoklosa T; Seferynska I; Bhatia R; Holyoake TL; Koschmieder S; Skorski T
Blood; 2013 May; 121(20):4175-83. PubMed ID: 23543457
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of tyrosine kinase inhibitors on a mouse chronic myeloid leukemia model and chronic myeloid leukemia stem cells.
Tanaka Y; Fukushima T; Mikami K; Adachi K; Fukuyama T; Goyama S; Kitamura T
Exp Hematol; 2020 Oct; 90():46-51.e2. PubMed ID: 32910995
[TBL] [Abstract][Full Text] [Related]
24. The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia.
Huang W; Luan CH; Hjort EE; Bei L; Mishra R; Sakamoto KM; Platanias LC; Eklund EA
Leukemia; 2016 Jul; 30(7):1502-9. PubMed ID: 26984787
[TBL] [Abstract][Full Text] [Related]
25. Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort?
Soverini S; De Santis S; Monaldi C; Bruno S; Mancini M
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209376
[TBL] [Abstract][Full Text] [Related]
26. Targeting quiescent leukemic stem cells using second generation autophagy inhibitors.
Baquero P; Dawson A; Mukhopadhyay A; Kuntz EM; Mitchell R; Olivares O; Ianniciello A; Scott MT; Dunn K; Nicastri MC; Winkler JD; Michie AM; Ryan KM; Halsey C; Gottlieb E; Keaney EP; Murphy LO; Amaravadi RK; Holyoake TL; Helgason GV
Leukemia; 2019 Apr; 33(4):981-994. PubMed ID: 30185934
[TBL] [Abstract][Full Text] [Related]
27. Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
Lin H; Chen M; Rothe K; Lorenzi MV; Woolfson A; Jiang X
Oncotarget; 2014 Sep; 5(18):8637-50. PubMed ID: 25226617
[TBL] [Abstract][Full Text] [Related]
28. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation.
Chomel JC; Bonnet ML; Sorel N; Sloma I; Bennaceur-Griscelli A; Rea D; Legros L; Marfaing-Koka A; Bourhis JH; Ame S; Guerci-Bresler A; Rousselot P; Turhan AG
Oncotarget; 2016 Jun; 7(23):35293-301. PubMed ID: 27167108
[TBL] [Abstract][Full Text] [Related]
29. Novel approaches to therapy in CML.
Bhatia R
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):115-120. PubMed ID: 29222245
[TBL] [Abstract][Full Text] [Related]
30. Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis.
Li H; Liu L; Zhuang J; Liu C; Zhou C; Yang J; Gao C; Liu G; Sun C
Mol Genet Genomic Med; 2019 Sep; 7(9):e851. PubMed ID: 31373443
[TBL] [Abstract][Full Text] [Related]
31. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
32. Chronic myeloid leukemia stem cells.
Houshmand M; Simonetti G; Circosta P; Gaidano V; Cignetti A; Martinelli G; Saglio G; Gale RP
Leukemia; 2019 Jul; 33(7):1543-1556. PubMed ID: 31127148
[TBL] [Abstract][Full Text] [Related]
33. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
[TBL] [Abstract][Full Text] [Related]
34. Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia.
Kamachi K; Ureshino H; Watanabe T; Yoshida N; Yamamoto Y; Kurahashi Y; Fukuda-Kurahashi Y; Hayashi Y; Hirai H; Yamashita S; Ushijima T; Okada S; Kimura S
Cancer Lett; 2022 Feb; 526():273-283. PubMed ID: 34875342
[TBL] [Abstract][Full Text] [Related]
35. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
[TBL] [Abstract][Full Text] [Related]
36. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.
Ng KP; Manjeri A; Lee KL; Huang W; Tan SY; Chuah CT; Poellinger L; Ong ST
Blood; 2014 May; 123(21):3316-26. PubMed ID: 24705490
[TBL] [Abstract][Full Text] [Related]
37. Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells.
Trinh A; Khamari R; Fovez Q; Mahon FX; Turcq B; Bouscary D; Maboudou P; Joncquel M; Coiteux V; Germain N; Laine W; Dekiouk S; Jean-Pierre S; Maguer-Satta V; Ghesquiere B; Idziorek T; Quesnel B; Kluza J; Marchetti P
Mol Metab; 2022 Jan; 55():101410. PubMed ID: 34863941
[TBL] [Abstract][Full Text] [Related]
38. Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment.
Shah M; Bhatia R
Adv Exp Med Biol; 2018; 1100():97-110. PubMed ID: 30411262
[TBL] [Abstract][Full Text] [Related]
39. Leukemia Stem Cells in Chronic Myeloid Leukemia.
Shan Y; DeSouza N; Qiu Q; Li S
Adv Exp Med Biol; 2019; 1143():191-215. PubMed ID: 31338821
[TBL] [Abstract][Full Text] [Related]
40. Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6.
Zhou M; Zhang X; Liu C; Nie D; Li S; Lai P; Jin Y
Oncogene; 2021 May; 40(20):3564-3577. PubMed ID: 33931742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
